Little Known Facts About ABBV-744 as a potential therapeutic option for aggressive cancers.
The current work examined the potential of utilizing ARV-825 and ABBV-744 to raise the effectiveness of tamoxifen or fulvestrant moreover palbociclib. ARV-825 was effective in both p53 wild-sort (WT) breast tumor cells and in cells lacking useful p53 both by itself or in combination with tamoxifen, while the effectiveness of ABBV-744 was limited to